Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 3Completed 2Active not recruiting 2Unknown 1Suspended 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 5Thoracic 3Gastrointestinal 2Dermatologic 2Breast 2Sarcoma 1Other solid neoplasm 1Gynecologic 1Genitourinary 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Liposarcoma 1Leiomyosarcoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Doxorubicin 25Radiotherapy 16apatinib 15Cyclophosphamide 15Ifosfamide 13anlotinib 12camrelizumab 10Temozolomide 9Imatinib Mesylate 9Vincristine 8Surgical Procedures, Operative 7Neoadjuvant Therapy 7Methotrexate 7Drug Therapy 7Dactinomycin 5Blood Specimen Collection 5fludarabine phosphate 4Paclitaxel 4Immune Checkpoint Inhibitors 4Etoposide 4Docetaxel 4Carboplatin 4toripalimab 3pembrolizumab 3Trabectedin 3Topotecan 3Surveys and Questionnaires 3Radiation Dose Hypofractionation 3Nivolumab 3Melphalan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × cemiplimab × Sarcoma × Clear all
NCT05094804 2023-11-02

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

OncoResponse, Inc.

Phase 1/2 Unknown
172 enrolled
DermatologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Leiomyosarcoma, Liposarcoma, Melanoma, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡